Intas peginterferon alfa-2b
Interferon alfa-2b biosimilar developed by Intas Pharmaceuticals. Reference product Intron A and PegIntron (Merck).
Brands by market: Brand not published by CDSCO (India) ยท Commercial partner or holder: Intas Pharmaceuticals
FDAnot listed
EMAnot listed
PMDAnot listed
HCnot listed
CDSCOApr 2013permitted
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union
Not listed by EMA.
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Central Drugs Standard Control OrganisationApprovedBrand
Not published by CDSCO (INN only)
Holder or applicant
Intas Biopharmaceuticals Ltd
Pathway
Similar Biologic, manufacture and marketing permission
Approved
Apr 2013
Application or permission
MF-89/2013
Indications as licensed
Chronic hepatitis C and B
Presentations
Pegylated interferon alfa-2b in vials and syringes
Source
S014
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- CDSCOApr 2013CDSCO permission granted
Sources
S014CDSCO, permissions granted in Form 46 and 46A, to 2019 Primary (regulator)
Planning interferon alfa-2b biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.